LGND Q2 2020 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M+65.8% YoY

Gross Profit

$34M81.5% margin

Operating Income

$7M17.1% margin

Net Income

$22M53.3% margin

EPS (Diluted)

$1.32

QoQ Revenue Growth

+24.9%

Cash Flow

Operating Cash Flow

$24M

Free Cash Flow

$24M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$548M

Stockholders' Equity

$695M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$25M	+65.8%
Gross Profit	$34M	$23M	+49.6%
Operating Income	$7M	-$4M	+271.9%
Net Income	$22M	-$14M	+253.2%

Revenue Segments

MaterialSalesCaptisolMember

$24M45%

Royalty

$7M13%

Kyprolis

$5M10%

Contract Revenue

$5M10%

Service

$5M9%

MilestoneMember

$3M6%

Evomela

$1M2%

LicenseFeesMilestonesandProductOtherProductOtherMember

$1M2%

LicenseFeesMember

$660,0001%

Royalty, Other

$501,0001%